REGENXBIO Inc.
Every calculator, already run for RGNX
Open the full toolkit →You have the numbers on RGNX. Get the argument.
A written report on which of these readings actually decide the outcome for REGENXBIO Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
11 analysts covering RGNXAnalyst Price Target Disagreement for REGENXBIO Inc.
Wall Street's bull case implies +576% from the current price; the bear case implies +35%. A 541% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for RGNX
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About REGENXBIO Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the com…
RGNX — frequently asked
Is RGNX a buy right now?
Wall Street's consensus rating on REGENXBIO Inc. is Buy across 11 analysts, with a mean price target of $23.73 (+221% vs. the current $7.40). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is RGNX's next earnings date?
REGENXBIO Inc. is next scheduled to report earnings around Nov 5, 2026. A full RGNX research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for REGENXBIO Inc.?
Analysts covering REGENXBIO Inc. (RGNX) range from a bear-case target of $10.00 to a bull-case high of $50.00, with a mean consensus target of $23.73 across 11 analysts. The spread of $40.00 (541% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare REGENXBIO Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For REGENXBIO Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full RGNX research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on REGENXBIO Inc., in minutes. 3 free reports included with every account — no credit card required.